Ultragenyx Pharmaceutical... (RARE)
NASDAQ: RARE
· Real-Time Price · USD
28.94
1.12 (4.03%)
At close: Sep 26, 2025, 1:12 PM
Ultragenyx Pharmaceutical Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|
| Product Revenue | 80.82M | 91.51M | 71.87M | 77.25M | 73.81M | 62.49M | 138.06M | 42.35M |
| Product Revenue Growth | -11.68% | +27.32% | -6.97% | +4.67% | +18.11% | -54.74% | +226.01% | n/a |
| Royalty Revenue | 85.68M | 47.78M | 93.01M | 62.24M | 73.22M | 46.34M | 126.95M | 55.7M |
| Royalty Revenue Growth | +79.30% | -48.62% | +49.43% | -14.99% | +57.99% | -63.49% | +127.90% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific Revenue | 4.2M | 3.29M | 3.57M | 2.31M | 3.05M | 35.18M | 18.25M | 17.23M | 19.07M | 22.8M | 8.26M | 14.12M | 12.54M | 9.79M | 70.89M | 66.91M | 75.57M | 87.74M | 82.73M | 72.65M |
| Asia Pacific Revenue Growth | +27.85% | -7.96% | +54.50% | -24.29% | -91.33% | +92.80% | +5.90% | -9.64% | -16.36% | +175.95% | -41.48% | +12.60% | +28.07% | -86.19% | +5.95% | -11.45% | -13.88% | +6.06% | +13.87% | n/a |
| Emea Revenue | 26.4M | 54.89M | 18.56M | 38.05M | 38.93M | 57.68M | 92.92M | 67.81M | 79.29M | 67.13M | 84.83M | 67.01M | 67.33M | 61.92M | n/a | n/a | n/a | n/a | n/a | n/a |
| Emea Revenue Growth | -51.90% | +195.76% | -51.22% | -2.26% | -32.51% | -37.92% | +37.02% | -14.48% | +18.11% | -20.86% | +26.59% | -0.47% | +8.74% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Latin America Revenue | 32.97M | 57.79M | 116.98M | 76.91M | 88.89M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Latin America Revenue Growth | -42.96% | -50.60% | +52.09% | -13.47% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| North America Revenue | 102.93M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| North America Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 86.65M | 87.8M | 82.5M | 80.35M | 80.6M | 78.16M | 76.83M | 74.92M | 81.4M | 76.65M | 72.85M | 69.84M | 68.14M | 67.31M | 59.43M | 53.88M | 53.41M | 53.26M | 51.04M | 42.12M | 42.25M | 47.52M | 41.88M | 41.01M | 39.81M | 38.83M | 34.48M | 31.09M | 30.72M | 31.43M | 37.72M | 23.5M | 20M | 18.68M | 19.81M | 17.18M | 14.74M | 13.21M | 11.59M | 10.23M | 7.04M | 4.14M |
| Selling, General, and Administrative Revenue Growth | -1.31% | +6.43% | +2.67% | -0.31% | +3.13% | +1.73% | +2.56% | -7.97% | +6.21% | +5.21% | +4.31% | +2.50% | +1.23% | +13.26% | +10.30% | +0.89% | +0.29% | +4.34% | +21.17% | -0.31% | -11.08% | +13.47% | +2.12% | +3.00% | +2.53% | +12.63% | +10.87% | +1.23% | -2.28% | -16.66% | +60.52% | +17.47% | +7.06% | -5.67% | +15.28% | +16.59% | +11.59% | +13.92% | +13.30% | +45.38% | +70.08% | n/a |
| Research and Development Revenue | 156.12M | 165.77M | 187.77M | 170.11M | 152.64M | 169.64M | 160.56M | 157.25M | 164.95M | 165.7M | 170.81M | 237.3M | 154.53M | 143.16M | 123.01M | 113.42M | 113.2M | 147.52M | 131.1M | 87.31M | 80.71M | 112.96M | 83.06M | 100.14M | 96.05M | 78.11M | 71.62M | 70.04M | 76.83M | 75.5M | 61.53M | 60.41M | 58.44M | 51.27M | 50.75M | 48.71M | 43.33M | 40.41M | 44.56M | 29.7M | 23.1M | 17.36M |
| Research and Development Revenue Growth | -5.82% | -11.71% | +10.38% | +11.44% | -10.02% | +5.66% | +2.11% | -4.67% | -0.45% | -2.99% | -28.02% | +53.56% | +7.95% | +16.37% | +8.46% | +0.19% | -23.26% | +12.52% | +50.15% | +8.18% | -28.55% | +36.00% | -17.06% | +4.27% | +22.97% | +9.06% | +2.25% | -8.84% | +1.76% | +22.72% | +1.85% | +3.38% | +13.98% | +1.03% | +4.18% | +12.41% | +7.22% | -9.31% | +50.03% | +28.57% | +33.06% | n/a |